Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Huang-Chih ChangChin-Chou WangChia-Cheng TsengKuo-Tung HuangYu-Mu ChenYu-Ping ChangChien-Hao LaiWen-Feng FangMeng-Chih LinHung-Yi ChuangPublished in: Thoracic cancer (2023)
This NMA suggests that afatinib results in similar PFS to erlotinib and superior PFS than gefitinib in patients with Del19 mutant NSCLC, aged ≥65 years, with ECOG scores of 0-1, and with baseline brain metastasis.